Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401323 · ClinicalTrials.gov registry record · Phase 2
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 568
- Enrollment target
NCT00401323: Completed Phase 2 study, sponsored by Sanofi.
NCT00401323 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 568 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (327% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00401323, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 568 participants
- Enrollment target
Study Summary
The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Interventions
- DRUG cisplatin
- DRUG 5-fluorouracil (5-FU)
- DRUG docetaxel (XRP6976)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 568 participants |
| Start Date | 1998-01 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
What the finished NCT00401323 record still lists
NCT00401323 is an interventional study that assigns participants to a tested intervention. The registered 568 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (327% higher).
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00401323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00401323 about?
NCT00401323 is a clinical study titled "Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma". The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
What is the current status of trial NCT00401323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 568 participants. The study started on 1998-01. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00401323?
The interventions under investigation include: cisplatin (DRUG), 5-fluorouracil (5-FU) (DRUG), docetaxel (XRP6976) (DRUG).
Who is sponsoring clinical trial NCT00401323?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00401323's enrollment target sits among peer trials
568 60th of 2000 higher than 1,941 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05472441 · 568 participants · NA
Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)
- NCT05000645 · 570 participants · NA
Grocery Delivery and Healthy Weight Gain Among Low-income Pregnant Young Women
- NCT06239844 · 570 participants · NA
Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English
- NCT06701903 · 570 participants · Phase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia